JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

JNJ

226.93

+0.75%↑

ABT

93.34

+0.83%↑

MDT

81.35

-2.02%↓

114.84

-0.43%↓

VEEV

158.17

-1.76%↓

Strona główna・Stock List・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Open

SectorHealthcare

21.06 1.69

Buy Sell

Overview

Share price change

24h

Current

Min

20.56

Max

21.44

Key metrics
By Trading Economics
Income	-7.3M -68M
Sales	23M 68M
Profit margin	-99.318
Employees	298
EBITDA	42M -15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+88.38% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	368M 2.1B
Previous open	19.37
Previous close	21.06

News Sentiment

By Acuity

50%

157 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

9.91 / 14.15 Support & Resistance

Syndax Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 kwi 2026, 23:15 UTC

Major News Events

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 kwi 2026, 23:08 UTC

Earnings

Major Market Movers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 kwi 2026, 23:58 UTC

Earnings

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 kwi 2026, 23:58 UTC

Earnings

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 kwi 2026, 23:56 UTC

Earnings

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 kwi 2026, 23:56 UTC

Earnings

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 kwi 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 kwi 2026, 23:34 UTC

Market Talk

Major News Events

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 kwi 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 kwi 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 kwi 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 kwi 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 kwi 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 kwi 2026, 22:10 UTC

Earnings

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 kwi 2026, 22:09 UTC

Earnings

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 kwi 2026, 21:56 UTC

Earnings

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 kwi 2026, 21:55 UTC

Earnings

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 kwi 2026, 21:55 UTC

Earnings

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 kwi 2026, 21:44 UTC

Earnings

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 kwi 2026, 21:43 UTC

Earnings

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 kwi 2026, 21:41 UTC

Earnings

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 kwi 2026, 21:41 UTC

Earnings

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 kwi 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

27 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27 kwi 2026, 20:39 UTC

Earnings

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Comparison

Price change

Syndax Pharmaceuticals Inc Forecast

Price Target

By TipRanks

88.38% upside

12 Months Forecast

Average 39.56 USD 88.38%

High 57 USD

Low 28 USD

Based on 10 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Syndax Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

9.91 / 14.15Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

157 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.